@article{b446bd3d6ad346b1ac02ab1065fc19ee,
title = "Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels",
abstract = "Background: In the trial of Minocycline in Clinically Isolated Syndrome (MinoCIS), minocycline significantly reduced the risk of conversion to clinically definite multiple sclerosis (CDMS). Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are emerging biomarkers in MS, and minocycline modulates matrix metalloproteinases (MMPs). Objective: To assess the value of blood NfL and GFAP as a biomarker of baseline and future disease activity and its utility to monitor treatment response in minocycline-treated patients with clinically isolated syndrome (CIS). Methods: We measured NfL, GFAP, and MMPs in blood samples from 96 patients with CIS from the MinoCIS study and compared biomarkers with clinical and radiologic characteristics and outcome. Results: At baseline, NfL levels correlated with T2 lesion load and number of gadolinium-enhancing lesions. Baseline NfL levels predicted conversion into CDMS at month 6. GFAP levels at baseline were correlated with T2 lesion volume. Minocycline treatment significantly increased NfL levels at 3 months but not at 6 months, and decreased GFAP levels at month 6. Minocycline decreased MMP-7 concentrations at month 1. Discussion: Blood NfL levels are associated with measures of disease activity in CIS and have prognostic value. Minocycline increased NfL levels at month 3, but reduced GFAP and MMP-7 levels.",
keywords = "CIS, GFAP, MMPs, Multiple sclerosis, NfL, minocycline",
author = "Carlos Camara-Lemarroy and Luanne Metz and Jens Kuhle and David Leppert and Eline Willemse and Li, {David K. B.} and Anthony Traboulsee and Jamie Greenfield and Graziela Cerchiaro and Claudia Silva and Yong, {V. Wee}",
note = "Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: E.W., C.S., G.C., J.G. and L.M. report no conflict of interest related to this manuscript. C.C.-L. received consulting fees from EMD Serono. J.K. received speaker fees, research support, travel support, and served on advisory boards by the Progressive MS Alliance, Swiss MS Society, Swiss National Research Foundation (320030_189140/1), University of Basel, Biogen, Celgene, Merck, Novartis, Octave Bioscience, Roche, and Sanofi. D.L. is Chief Medical Officer of GeNeuro. D.K.B.L. has received research funding from the Multiple Sclerosis Society of Canada. He is Emeritus Director of the UBC MS/MRI Research Group that has been contracted to perform central analysis of MRI scans for therapeutic trials with Roche and Sanofi-Genzyme. The UBC MS/MRI Research Group has also received grant support for investigator-initiated studies from Genzyme, Novartis, and Roche. He has been a consultant to Vertex Pharmaceuticals and Genzyme, served on the Scientific Advisory Board for Celgene and the PML-MS Steering Committee for Biogen. He has given lectures, supported by non-restricted education grants from Academy of Health Care Learning, Consortium of MS Centers and Sanofi-Genzyme. A. Traboulsee has received research funding from MS Society of Canada, Roche, and Sanofi-Genzyme; received honoraria or travel support from Consortium of MS Centers, Biogen, Teva, Roche, Merck/EMD Serono, and Sanofi-Genzyme. W.Y. has received honoraria from Biogen, EMD Serono, Novartis, Roche, and Sanofi-Genzyme. He is the recipient of unrestricted educational grants from Biogen, EMD Serono, Novartis, Roche, Sanofi-Genzyme, and Teva to support educational activities of the Alberta MS Network, which he directs. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This biomarker research study was supported by funds to the Alberta Multiple Sclerosis Collaboration from the Ministry of Economic Development, Trade and Tourism, and the Ministry of Health of the Government of Alberta. Publisher Copyright: {\textcopyright} The Author(s), 2022.",
year = "2022",
month = nov,
doi = "https://doi.org/10.1177/13524585221109761",
language = "English",
volume = "28",
pages = "2081--2089",
journal = "MULTIPLE SCLEROSIS JOURNAL",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "13",
}